|38.39||-0.9500||-2.41%||Vol 4.30M||1Y Perf 2.97%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||-0.04 -0.10%|
|Target Price||46.90||Analyst Rating||Moderate Buy 2.27|
|Potential %||22.17||Finscreener Ranking||★★ 46.38|
|Insiders Trans % 3/6/12 mo.||100/100/93||Value Ranking||★+ 43.37|
|Insiders Value % 3/6/12 mo.||100/100/61||Growth Ranking||★★ 47.27|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/62||Income Ranking||★+ 35.36|
|Price Range Ratio 52W %||54.46||Earnings Rating||Neutral|
|Market Cap||103.37B||Earnings Date||27th Oct 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Oct 2021|
|Estimated EPS Next Report||0.80|
|EPS Growth Next 5 Years %||6.80|
|Avg. Weekly Volume||4.41M|
|Avg. Monthly Volume||3.60M|
|Avg. Quarterly Volume||3.60M|
GlaxoSmithKline PLC (NYSE: GSK) stock closed at 38.39 per share at the end of the most recent trading day (a -2.41% change compared to the prior day closing price) with a volume of 4.36M shares and market capitalization of 103.37B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 99437 people. GlaxoSmithKline PLC CEO is Emma N. Walmsley.
The one-year performance of GlaxoSmithKline PLC stock is 2.97%, while year-to-date (YTD) performance is 4.32%. GSK stock has a five-year performance of -11.58%. Its 52-week range is between 33.26 and 42.68, which gives GSK stock a 52-week price range ratio of 54.46%
GlaxoSmithKline PLC currently has a PE ratio of 15.50, a price-to-book (PB) ratio of 4.60, a price-to-sale (PS) ratio of 2.41, a price to cashflow ratio of 11.20, a PEG ratio of 2.32, a ROA of 5.59%, a ROC of 11.88% and a ROE of 31.09%. The company’s profit margin is 15.54%, its EBITDA margin is 32.30%, and its revenue ttm is $40.52 Billion , which makes it $16.11 revenue per share.
Of the last four earnings reports from GlaxoSmithKline PLC, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.80 for the next earnings report. GlaxoSmithKline PLC’s next earnings report date is 27th Oct 2021.
The consensus rating of Wall Street analysts for GlaxoSmithKline PLC is Moderate Buy (2.27), with a target price of $46.9, which is +22.17% compared to the current price. The earnings rating for GlaxoSmithKline PLC stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
GlaxoSmithKline PLC has a dividend yield of 5.46% with a dividend per share of $2.12 and a payout ratio of 76.00%.
GlaxoSmithKline PLC has a Sell technical analysis rating based on Technical Indicators (ADX : 7.42, ATR14 : 0.51, CCI20 : -119.01, Chaikin Money Flow : -0.21, MACD : -0.53, Money Flow Index : 23.52, ROC : -5.26, RSI : 29.25, STOCH (14,3) : 2.68, STOCH RSI : 0.05, UO : 38.99, Williams %R : -97.32), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of GlaxoSmithKline PLC in the last 12-months were: Charles A. Bancroft (Buy at a value of $128 643), Emma N. Walmsley (Buy at a value of $1 500), Emma N. Walmsley (Sold 32 346 shares of value $391 613 ), Hal V Barron (Buy at a value of $12 067 774), Hal V Barron (Sold 173 710 shares of value $3 100 532 ), Jesse Goodman (Buy at a value of $53 439), Jonathan Richard Symonds (Buy at a value of $569 634), Jonathan Richard Symonds (Sold 17 888 shares of value $235 567 ), Judy C. Lewent (Buy at a value of $55 225), Laurie H. Glimcher (Buy at a value of $162 010), Lynn Laverty Elsenhans (Buy at a value of $76 321), Manvinder Singh Banga (Buy at a value of $539 687), Urs Rohner (Buy at a value of $33 755), Vivienne Cox (Buy at a value of $33 755)
Mon, 23 Aug 2021 10:32 GMT A Look at 23andMes Earnings and Risk Factors Amid Therapeutic Efforts- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.